Baseline patient characteristics of the 2 treatment groups.
| Variable, n | ASA Only (n = 43) | LMWH/ASA (n = 45) |
|---|---|---|
| History of early losses (≤ 14 wks) | 34 | 32 |
| History of late losses (> 14 wks) | 9 | 13 |
| Still birth ever (20–32 wks) | 7 | 4 |
| Live birth ever | 15 | 15 |
| Maternal age at randomization, yrs, mean (SD) | 33.8 (4.1) | 34.6 (3.9) |
| Gestational age at randomization, wks, mean (SD) | 5.6 (1.5) | 5.8 (1.5) |
| Current smoker | 3 | 5 |
| aPL (aCL and/or LAC) | 20 | 22 |
| Inherited thrombophilia | 10* | 9** |
| ANA | 15 | 15 |
| ≥ 2 Laboratory abnormalities | 4 | 7 |
ASA: aspirin; LMWH: low molecular weight heparin; aPL: antiphospholipid antibody; aCL: anticardiolipin antibody; LAC: lupus anticoagulant; ANA: antinuclear antibody; SD: standard deviation.
↵* 7 heterozygous for Factor V Leiden, 3 heterozygous for prothrombin 20210 AG.
↵** 7 heterozygous for Factor V Leiden, 1 heterozygous for prothrombin 20210AG, and 1 heterozygous for both prothrombin 20210 AG and methylenetetrahydrofolate reductase (MTHFR).